AMPE - Ampion updates on COVID-19 trial progress

Ampio Pharmaceuticals (AMPE) has launched a global clinical trial for the IV formulation of its lead asset Ampion for treating COVID-19 patients including in out-patient settings. It has also provided updates on Phase I clinical trial for the inhaled formulation of the Ampion currently underway in the U.S.The new global study to assess the effect of Ampion IV treatment in both a hospital setting and as a therapy for out-patient care is currently taking place in the U.S. and Israel, targeting the systemic inflammation of patients with moderate to severe COVID-19 symptoms.The Phase 1 trial for inhalational Ampion mainly evaluates the impact of the therapy in patients with respiratory distress due to COVID-19. The U.S.-based study is currently in progress, with no drug-related serious adverse events ("SAEs") reported to date. Once the frontline healthcare workers receive the COVID-19 vaccination, the study enrollment will accelerate, the company says, expecting to complete the patient

For further details see:

Ampion updates on COVID-19 trial progress